Skip to main content

Table 4 Cardiac findings in SSc patients with myocardial involvement

From: The clinical characteristics and outcomes of patients with systemic sclerosis with myocardial involvement

Patient

Age of MI (years)

Duration of MI (months)

Heart failure

Elevated CTni

Elevated NT-proBNP

ECG

Echo

CMR

1

14

2

Y

Y

Y

Ventricular arrhythmia

Cardiomyopathy

LGE +

2

21

2

Y

Y

Y

-

LVEF < 50%

LGE +

3

29

27

Y

Y

Y

Atrioventricular block

Wall motion abnormality LVEF < 50%

LGE + Ventricular hypertrophy

4

34

34

Y

Y

Y

-

LVEF < 50%

NA

5

34

124

N

Y

Y

Ventricular arrhythmia

Cardiomyopathy

Ventricular hypertrophy

Ventricular hypertrophy

6

35

80

Y

Y

Y

Ventricular hypertrophy

Cardiomyopathy LVEF < 50%

NA

7

35

7

Y

Y

Y

-

Wall motion abnormality LVEF < 50%

NA

8

37

28

N

Y

N

-

Ventricular hypertrophy

NA

9

38

37

Y

N

Y

Supraventricular arrhythmia

Wall motion abnormality

LGE +

10

45

0

Y

N

Y

-

Cardiomyopathy LVEF < 50%

LGE +

11

44

12

Y

Y

Y

Atrioventricular block

Cardiomyopathy LVEF < 50%

Wall motion abnormality

12

52

61

N

N

N

Ventricular arrhythmia

-

LGE +

13

51

2

N

N

N

-

-

LGE + Ventricular hypertrophy

14

55

13

N

NA

Y

-

Cardiomyopathy

Ventricular hypertrophy

LVEF < 50%

NA

15

55

108

N

Y

N

-

-

LGE +

Ventricular hypertrophy

16

60

130

Y

Y

Y

Ventricular arrhythmia

-

LGE +

17

60

5

Y

Y

Y

Atrioventricular block

LVEF < 50%

NA

18

62

205

N

N

Y

-

Wall motion abnormality

LGE + Ventricular hypertrophy

19

64

2

N

Y

Y

-

Ventricular enlargement

Ventricular enlargement

20

68

55

N

NA

Y

-

LVEF < 50%

LGE + Ventricular hypertrophy

21

69

20

N

Y

Y

Atrial fibrillation

-

LGE + Ventricular hypertrophy

  1. CTnI: cardiac troponin I; NTproBNP: N-terminal pro-brain natriuretic peptide; CMR: cardiac magnetic resonance; LV: left ventricular; EF: Ejection fraction; LGE: late gadolinium enhancement; NA: not available; Y: yes; N: No; -: normal